We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
163 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XGEVA denosumab (rch) 120 mg/mL solution for injection pre-filled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for REXADEV denosumab (rch) 60mg/1mL solution for injection prefilled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CORORA denosumab (rch) 60mg/1mL solution for injection prefilled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZEROUNT denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEPTARGIS denosumab (rch) 60mg/1mL solution for injection prefilled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GANVADO denosumab (rch) 70mg/mL (120mg/1.7mL) solution for injection vial.
-
Australian Public Assessment Report (AusPAR)Kyprolis (carfilzomib) has been approved to treat relapsed or refractory multiple myeloma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.